牛皮关节炎:发展,检测和预防:一个范围审查
Agnieszka Kimak1, Ewa Robak1, Joanna Makowska2
1Department of Dermatology and Venereology, Medical University of Lodz, Hallera 1, 90-647 Lodz, Poland.
Journal of clinical medicine
|June 10, 2023
概括
牛皮关节炎 (PsA) 是一种慢性炎症性疾病. 在生物标志物和超声波的帮助下,早期诊断和干预是管理和潜在地预防PsA进展的关键.
科学领域:
- 风湿病学和皮肤病学
- 慢性炎症疾病研究 慢性炎症疾病研究
- 生物标志物发现和医学成像
背景情况:
- 牛皮关节炎 (PsA) 是一种异质的,慢性炎症状况,在一些牛皮患者中发展.
- 病程和PsA的临床表现是高度可变的.
- 早期诊断,多学科护理和药物治疗方面的重大进展已经改变了PsA管理.
研究的目的:
- 审查有关牛皮关节炎的诊断,管理和预防的当前观点和证据.
- 突出PsA风险因素和早期关节炎症状查的重要性.
- 讨论可溶性生物标志物和先进成像技术的新兴研究,以改善PsA预测.
主要方法:
- 关于牛皮关节炎诊断,治疗和预防策略的当前文献的综述.
- 评估超声波在检测PsA的亚临床炎症中的作用.
- 基于系统性牛皮治疗的早期干预潜力的分析.
主要成果:
- 超声波检测在识别亚临床炎症方面具有很高的准确性,这对于早期发现PsA至关重要.
- 早期诊断和干预至关重要,有可能预防或延迟PsA发病.
- 研究正在积极探索新的生物标志物和成像技术,以提高PsA预测.
结论:
- 早期检测和干预对于治疗牛皮关节炎至关重要.
- 超声波是识别亚临床炎症的宝贵工具.
- 对生物标志物和成像的持续研究将进一步完善PsA预测和预防策略.
相关概念视频
Genome-wide Association Studies-GWAS
13.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.6K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
19
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
19
Atherosclerosis III: Management
15
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
15
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
38
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
38
Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Pharmacovigilance
914
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
914


